Is there a place for AMH testing in Canada?

Area of Science:

• Reproductive Endocrinology
• Gynecology
• Biomarker Discovery

Background:

• Anti-Müllerian hormone (AMH) is a glycoprotein with established roles in male sexual development.
• Emerging research highlights AMH's significance in female reproductive processes, particularly ovarian folliculogenesis.

Purpose of the Study:

• To evaluate the utility of serum AMH measurements as a marker of ovarian reserve.
• To explore AMH's potential in predicting menopause onset and ovarian response to stimulation.
• To assess the feasibility of universal AMH testing in Canada.

Main Methods:

• Review of existing studies on serum AMH levels and their correlation with ovarian parameters.
• Analysis of AMH's association with antral follicle count and its cycle variability.
• Evaluation of AMH's predictive capabilities for menopausal age and in vitro fertilization outcomes.

Main Results:

• Serum AMH levels strongly correlate with antral follicle count, indicating its efficacy as an ovarian reserve marker.
• AMH demonstrates minimal cycle-to-cycle variability and declines predictably with age.
• AMH levels can predict ovarian stimulation response and risk of OHSS in IVF patients.

Conclusions:

• Serum AMH is a reliable and advantageous marker for assessing ovarian reserve.
• AMH testing shows potential for predicting menopause and guiding fertility treatments.
• The favorable characteristics of AMH testing warrant consideration for universal implementation in Canada.